ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • Register
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 1125

Health Care Resource Utilization and Costs in Patients with Juvenile Idiopathic Arthritis Treated with Abatacept and Other Targeted Disease Modifying Anti-rheumatic Drugs

Joe Zhuo1, Ying Bao 2, Qian Xia 2, Aarti Rao 3, Niyati Sharma 3, Xue Han 4 and Robert Wong 5, 1Bristol-Myers Squibb, Princeton, NJ, 2Bristol-Myers Squibb, Lawrenceville, NJ, 3Mu Sigma, Bangalore, India, 4Bristol-Myers Squibb Company, Princeton, NJ, 5Bristol-Myers Squibb, Princeton

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: Abatacept and health care cost, juvenile idiopathic arthritis (JIA)

  • Tweet
  • Email
  • Print
Save to PDF
Session Information

Date: Monday, November 11, 2019

Session Title: Health Services Research Poster II – ACR/ARP

Session Type: Poster Session (Monday)

Session Time: 9:00AM-11:00AM

Background/Purpose: Juvenile idiopathic arthritis (JIA) is a common, chronic rheumatic disease of childhood that carries substantial economic impact on patients (pts) and families1. The objective of this study was to evaluate the healthcare resource utilization and costs of JIA pts treated with abatacept (ABA) vs. other biologics and targeted disease modifying anti-rheumatic drugs (tDMARDs).

Methods: Pts (age < 18 years) from Truven’s MarketScan US Commercial Claims and Encounters claims database with ≥ 2 diagnoses of JIA (ICD-9: 714.3x or ICD-10: M08.xxx) separated by at least one day between 1 July 2006 till 31 March 2018 were split into 2 mutually exclusive cohorts of pts taking ABA vs. other tDMARDs as initial treatment on or after first JIA diagnosis. Index date was defined as the first prescription date for the drugs of interest. Healthcare resource use including inpatient, outpatient, emergency, urgent care visit and pharmacy visits and costs were calculated for the 6 months’ pre-index period and post-index period (index date till date of treatment switching, discontinuation, enrollment end or 183 days, whichever is earliest). The other tDMARDs pts were also stratified by TNF vs. non TNF pts.  Statistical differences were assessed using chi-square and Kruskal-Wallis tests with significance level of 0.05.

Results: A total of 1,704 pts (26 ABA and 1,678 biologics and other tDMARD pts) were included in the analysis. ABA pts are more likely to be female, have a longer disease duration and had more prior biologic use (Table 1). The number of total healthcare visit decreased by 2.31 per pt in ABA pts but increased by 1.49 per pt in other tDMARD pts. (Table 2) The difference was primarily driven by the change of pharmacy visits ( -2.12 per ABA pt vs. +3.16 per other tDMARDs pt) As a result, the increase in the pharmacy related costs for other tDMARDs pts was $5,660.3 more than that in ABA pts (Table 3). The increase of total cost over time was numerically greater in other tDMARD pts, TNF pts and non-TNF pts although the differences were not statistically significant. 

Conclusion: Despite a longer disease duration, pts initiated with ABA had a greater decrease in pharmacy visit and related cost in comparison with other tDMARDs pts. Further analysis is warranted to understand the cause of the differences and its implications.


Table1

Table1: Baseline Demographic and Clinical Patient Characteristics


Table2

Table2: Change in HealthCare Resource Utilization Associated with the Initiation of Abatacept vs. Other tDMARDs


Table3

Table3: Change in medical costs among patients treated with abatacept and other tDMARDs


Disclosure: J. Zhuo, Bristol-Myers Squibb, 1, 3; Y. Bao, BMS, 1, 3, Bristol-Myers Squibb Company, 3, 4; Q. Xia, Bristol-Myers Squibb Company, 3, 4; A. Rao, None; N. Sharma, None; X. Han, Bristol-Myers Squibb, 3, Bristol-Myers Squibb Company, 3; R. Wong, Bristol-Myers Squibb, 3, 4.

To cite this abstract in AMA style:

Zhuo J, Bao Y, Xia Q, Rao A, Sharma N, Han X, Wong R. Health Care Resource Utilization and Costs in Patients with Juvenile Idiopathic Arthritis Treated with Abatacept and Other Targeted Disease Modifying Anti-rheumatic Drugs [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/health-care-resource-utilization-and-costs-in-patients-with-juvenile-idiopathic-arthritis-treated-with-abatacept-and-other-targeted-disease-modifying-anti-rheumatic-drugs/. Accessed April 17, 2021.
  • Tweet
  • Email
  • Print
Save to PDF

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/health-care-resource-utilization-and-costs-in-patients-with-juvenile-idiopathic-arthritis-treated-with-abatacept-and-other-targeted-disease-modifying-anti-rheumatic-drugs/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Convergence: Where Rheumatology Meets. All Virtual. November 5-9.

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2021 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.